Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study

Fig. 2

AAA-1 affect triglyceride metabolism. Western Blot assay was performed using HepaRG cells lysates, untreated, treated with Ctrl IgG or with AAA-1 for 24 h, a AAA-1, but not control antibodies, dramatically increase the active form of SREBP-1 while SREBP-2 expression is not affected. P-value calculated with Mann–Whitney test. ** P = 0.008, ## P = 0.007; in b FASN and GPAT1 expression is strongly decreased after 24 h AAA-1 treatment. * P = 0.011, # P = 0.023, *** P = 0.001. In c Cells were treated with AAA-1 at different time points. * P = 0.029, *** P = 0.001, **** P < 0.001. One of three representative western blot is shown in each panel. Under each panel, respective data are expressed as scatter dot plot and median with range of band intensity volume/actin or tubulin intensity volume from three different experiments (n = 3). P-value calculated with Mann–Whitney test in a and b and with Kruskal–Wallis test in panel c). SREBP: Sterol regulatory element binding protein. FASN: Fatty acid synthetase. GPAT: Glycerol phosphate acyltransferase

Back to article page